Since arginine is required by a variety of cancer cells, especially those that are highly proliferating (17, 18), therapeutic arginine deprivation in ASS1-deficient cancers has been examined as a potential anticancer strategy in a number of tumor types, including our own studies in GBM (19–21). This evidence concerns the gene ASS1 and glioblastoma.